Knight-Madden Jennifer M, Hambleton Ian R
Sickle Cell Unit, Tropical Medicine Research Institute, University of the West Indies, Mona, Kingston 7, Jamaica.
Cochrane Database Syst Rev. 2016 Sep 27;9(9):CD003733. doi: 10.1002/14651858.CD003733.pub4.
Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome. This is an update of a previously published Cochrane Review.
To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome.
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and Embase (1981 to 2002).Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 11 July 2016.
Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.
We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
AUTHORS' CONCLUSIONS: If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.
支气管扩张剂用于治疗哮喘中的支气管高反应性。支气管高反应性可能是镰状细胞病患者急性胸综合征的一个组成部分。因此，支气管扩张剂可能对急性胸综合征的治疗有用。这是对先前发表的Cochrane系统评价的更新。
评估支气管扩张剂用于急性胸综合征患者的获益和风险。
我们检索了Cochrane囊性纤维化和遗传疾病组试验注册库，其中包括通过全面电子数据库检索、相关期刊手工检索以及会议论文摘要集识别出的参考文献。另外还在MEDLINE（1966年至2002年）和Embase（1981年至2002年）上进行了检索。该组血红蛋白病试验注册库的最新检索日期：2016年7月11日。
随机或半随机对照试验。如果有足够证据表明治疗组和对照组在基线时相似，使用半随机化方法的试验将纳入本评价的未来更新版。
我们未发现研究支气管扩张剂用于镰状细胞病患者急性胸综合征的试验。
我们未发现研究支气管扩张剂用于镰状细胞病患者急性胸综合征的试验。
如果支气管高反应性是镰状细胞病患者某些急性胸综合征发作的重要组成部分，则可能需要使用吸入性支气管扩张剂。需要进行一项设计良好、样本量充足的随机对照试验，以评估在镰状细胞病患者急性胸综合征的既定治疗方案中加用吸入性支气管扩张剂的获益和风险。
